Log in
Log in
Or log in with
GoogleGoogle
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Apple Apple     

Business Leaders

HomeAll NewsMost read newsBusiness Leaders Biography 
Portrait de Joaquin Duato
Age : 59
Public asset : 45,424,230 USD
Country of residence : Unknown
Linked companies : Johnson & Johnson

Summary 
Mr. Joaquin Duato is a Chairman & Chief Executive Officer at Johnson & Johnson.

He is on the Board of Directors at U.S.-Spain Council, Inc. and Save The Children Federation, Inc. Mr. Duato was previously employed as an Independent Director by Hess Corp., a President by Ortho Biotech Products LP, a Managing Director by Janssen-Cilag SpA, and a Chairman by Pharmaceutical Research & Manufacturers of America.

He also served on the board at United States Fund for UNICEF and CEO Roundtable on Cancer, Inc.

He received his graduate degree from Thunderbird School of Global Management and an MBA from Escuela Superior de Administraciˇn y Direcciˇn de Empresas.




Current positions of Joaquin Duato 
Holdings of Joaquin Duato 
Joaquin Duato : Personal Network 
Most Read News 
11/28Buffett's Berkshire countersues billionaire Haslams in battle over Pilot valuation
RE
11/30Tesla to deliver Cybertrucks after Musk tempers expectations
MR
11/28Charlie Munger, the 'Oracle of Pasadena' who was Buffett's second-in-command
RE
11/27Elon Musk, Netanyahu tour ruins of Israeli kibbutz
RE
11/28Berkshire Hathaway vice chairman Charlie Munger dies at 99
RE
11/26Germany's Kuehne examines offer for Signa's Hamburg skyscraper -report
RE
11/30BP's search for new CEO to extend into next year as Looney probe drags on
RE
12/01Lagardère: three chargés de mission appointed
CF
11/28Elon Musk promises to wear symbol of Gaza hostages
RE
11/29Lagardère: Maxime Saada appointed Vice-Chairman
CF
More news


© 2023 People and Ownership :   
Joaquin Duato : Connections 


Latest news about Joaquin Duato 
12/05Transcript : Johnson & Johnson - Special Call
CI
12/04Health Up as Pfizer Slides -- Health Care Roundup
DJ
11/30Johnson & Johnson Names Eugene Woods as Board Member
DJ
10/17Transcript : Johnson & Johnson, Q3 2023 Earnings Call, Oct 17, 2023
CI
10/17Johnson & Johnson Lifts Full-Year Guidance Following Third-Quarter Beat
MT
09/29Johnson & Johnson Urged by Health Aid Agency to Allow Generic Tuberculosis Drug by Removing Secondary Patents
MT
More news

As early as today, start finding the best investment opportunities!Optimize my profits
Optimize my profits